Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 4/20 | 0.53 |
| ▸ | DRD1 | P21728 | 2/20 | 0.53 |
| ▸ | DRD5 | P21918 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14852694 | 0.89 | HTR2C (0.50) | DRD2DRD3DRD1DRD5HTR2C | |
| SCHEMBL12905306 | 0.82 | DRD3 (0.50) | DRD2DRD3DRD1DRD5HTR2C | |
| SCHEMBL27010072 | 0.77 | DRD2 (0.49) | DRD2DRD3DRD1DRD5HTR2C | |
| SCHEMBL29187833 | 0.77 | HRH3 (0.51) | DRD2DRD3MEN1KMT2A | |
| SCHEMBL28598103 | 0.76 | MEN1 (0.54) | DRD2DRD3DRD1DRD5HTR2C | |
| SCHEMBL30826401 | 0.76 | MCHR1 (0.40) | DRD2DRD3DRD1DRD5HTR2C | |
| SCHEMBL29187834 | 0.76 | MCHR1 (0.40) | DRD2DRD3DRD1DRD5HTR2C | |
| SCHEMBL21232729 | 0.75 | NOTUM (0.63) | DRD2DRD3DRD1DRD5SMN1; SMN2 | |
| SCHEMBL2625804 | 0.75 | ALOX12 (0.50) | DRD2DRD3DRD1DRD5HTR2C | |
| SCHEMBL23976082 | 0.74 | DRD1 (0.76) | DRD2DRD3DRD1DRD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | CRY2, CYP2J2, NR0B2 | DRD2 353/4885DRD3 339/4885DRD1 192/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | DRD2 4565/4885DRD3 4418/4885DRD1 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.